[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:mrc1-wt-allele":3},{"name":4,"total":5,"recruiting":6,"trials":7},"MRC1 wt Allele",77,69,[8,15,22,28,34,41,48,55,61,68,74,80,86,92,98,104,110,116,123,129,135,141,147,152,158,164,169,175,181,187,193,199,204,210,216,222,228,234,240,245,251,257,263,269,275,281,287,293,299,305],{"nct_id":9,"title":10,"phases":11,"status":12,"updated_at":13,"content_modified":14},"NCT07270666","ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer",[],"RECRUITING","2026-08-26T02:16:20.336282Z","2026-07-19T19:36:05.068430Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06843434","A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma",[19],"Phase 2","2026-08-26T02:15:22.311223Z","2026-07-05T05:32:16.700719Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT07235293","A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.",[19],"2026-08-26T02:17:32.059863Z","2026-07-05T05:32:16.670680Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT07594015","Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy",[19],"2026-08-26T02:18:33.598205Z","2026-05-29T15:36:40.203701Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":39,"content_modified":40},"NCT07128355","Botensilimab, Balstilimab, and SBRT in Colorectal Cancer",[38],"Early Phase 1","2026-08-26T02:18:38.077159Z","2026-05-05T02:43:29.536064Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":46,"content_modified":47},"NCT06952504","A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033\u002FTroFuse-033\u002FGOG-3119\u002FENGOT-en29)",[45],"Phase 3","2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.464456Z",{"nct_id":49,"title":50,"phases":51,"status":12,"updated_at":53,"content_modified":54},"NCT05174169","Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease",[52],"Phase 2\u002FPhase 3","2026-08-26T02:18:26.932189Z","2026-05-05T02:43:29.353861Z",{"nct_id":56,"title":57,"phases":58,"status":12,"updated_at":59,"content_modified":60},"NCT05672524","A Study of Tucatinib and Trastuzumab in People With Rectal Cancer",[19],"2026-08-26T02:17:00.709807Z","2026-05-05T02:43:29.285490Z",{"nct_id":62,"title":63,"phases":64,"status":12,"updated_at":66,"content_modified":67},"NCT04991948","Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer",[65],"Phase 1","2026-08-26T02:16:22.235886Z","2026-05-05T02:43:29.232449Z",{"nct_id":69,"title":70,"phases":71,"status":12,"updated_at":72,"content_modified":73},"NCT07446322","FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer",[19],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:29.132436Z",{"nct_id":75,"title":76,"phases":77,"status":12,"updated_at":78,"content_modified":79},"NCT06366347","ALPINE: Maintenance Letrozole\u002FAbemaciclib",[19],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:28.884662Z",{"nct_id":81,"title":82,"phases":83,"status":12,"updated_at":84,"content_modified":85},"NCT07082439","Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma",[19],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.856382Z",{"nct_id":87,"title":88,"phases":89,"status":12,"updated_at":90,"content_modified":91},"NCT06989112","DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+\u002F2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer",[45],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:28.516336Z",{"nct_id":93,"title":94,"phases":95,"status":12,"updated_at":96,"content_modified":97},"NCT04774419","Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery",[19],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.401063Z",{"nct_id":99,"title":100,"phases":101,"status":12,"updated_at":102,"content_modified":103},"NCT06589440","Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)",[19],"2026-08-26T02:18:56.409949Z","2026-05-05T02:43:28.346454Z",{"nct_id":105,"title":106,"phases":107,"status":12,"updated_at":108,"content_modified":109},"NCT07198074","Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer",[45],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:28.219924Z",{"nct_id":111,"title":112,"phases":113,"status":12,"updated_at":114,"content_modified":115},"NCT06459869","NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer",[65],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.131496Z",{"nct_id":117,"title":118,"phases":119,"status":12,"updated_at":121,"content_modified":122},"NCT06267729","Study of AZD0754 in Participants With Metastatic Prostate Cancer",[120],"Phase 1\u002FPhase 2","2026-08-26T02:16:55.892527Z","2026-05-05T02:43:28.077996Z",{"nct_id":124,"title":125,"phases":126,"status":12,"updated_at":127,"content_modified":128},"NCT07292298","Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates",[19],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:27.930465Z",{"nct_id":130,"title":131,"phases":132,"status":12,"updated_at":133,"content_modified":134},"NCT06792695","A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer",[19],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:27.846810Z",{"nct_id":136,"title":137,"phases":138,"status":12,"updated_at":139,"content_modified":140},"NCT06205485","Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer",[45],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:27.846766Z",{"nct_id":142,"title":143,"phases":144,"status":12,"updated_at":145,"content_modified":146},"NCT07147231","Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer",[120],"2026-08-26T02:18:46.948970Z","2026-05-05T02:43:27.838424Z",{"nct_id":148,"title":149,"phases":150,"status":12,"updated_at":39,"content_modified":151},"NCT05603910","Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent\u002FUnresectable Endometrial Carcinoma",[65],"2026-05-05T02:43:27.804429Z",{"nct_id":153,"title":154,"phases":155,"status":12,"updated_at":156,"content_modified":157},"NCT05239546","Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers",[19],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:27.753684Z",{"nct_id":159,"title":160,"phases":161,"status":12,"updated_at":162,"content_modified":163},"NCT07550088","BAL\u002FBOT\u002FagenT-797 in pMMR CRC With Liver Metastases",[19],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:27.605002Z",{"nct_id":165,"title":166,"phases":167,"status":12,"updated_at":139,"content_modified":168},"NCT06369155","Azenosertib in Uterine Serous Carcinoma: Biomarker Study",[19],"2026-05-05T02:43:27.506641Z",{"nct_id":170,"title":171,"phases":172,"status":12,"updated_at":173,"content_modified":174},"NCT05854498","Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer",[19],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.259660Z",{"nct_id":176,"title":177,"phases":178,"status":12,"updated_at":179,"content_modified":180},"NCT05855200","Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR\u002FMSI-H Resectable Colon Cancer",[45],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.110176Z",{"nct_id":182,"title":183,"phases":184,"status":12,"updated_at":185,"content_modified":186},"NCT06529523","Tislelizumab in People With Colorectal Cancer",[19],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:27.088777Z",{"nct_id":188,"title":189,"phases":190,"status":12,"updated_at":191,"content_modified":192},"NCT07403721","AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H\u002FdMMR Solid Tumors",[65],"2026-08-26T02:18:17.950264Z","2026-05-05T02:43:26.954091Z",{"nct_id":194,"title":195,"phases":196,"status":12,"updated_at":197,"content_modified":198},"NCT07277322","Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases",[120],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:26.932462Z",{"nct_id":200,"title":201,"phases":202,"status":12,"updated_at":179,"content_modified":203},"NCT06411691","KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer",[65],"2026-05-05T02:43:26.921409Z",{"nct_id":205,"title":206,"phases":207,"status":12,"updated_at":208,"content_modified":209},"NCT07281768","Capecitabine\u002FOxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer",[19],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:26.902180Z",{"nct_id":211,"title":212,"phases":213,"status":12,"updated_at":214,"content_modified":215},"NCT07172282","INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases",[38],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:26.748582Z",{"nct_id":217,"title":218,"phases":219,"status":12,"updated_at":220,"content_modified":221},"NCT06992258","A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced\u002FMetastatic Colorectal Cancer",[19],"2026-08-26T02:15:33.331531Z","2026-05-05T02:43:26.739079Z",{"nct_id":223,"title":224,"phases":225,"status":12,"updated_at":226,"content_modified":227},"NCT07416552","A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)",[65],"2026-08-26T02:17:45.190188Z","2026-05-05T02:35:31.934070Z",{"nct_id":229,"title":230,"phases":231,"status":12,"updated_at":232,"content_modified":233},"NCT06205836","Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer",[19],"2026-08-26T02:18:14.396999Z","2026-05-05T02:35:31.706349Z",{"nct_id":235,"title":236,"phases":237,"status":12,"updated_at":238,"content_modified":239},"NCT05870800","Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER",[19],"2026-08-26T02:18:22.309547Z","2026-05-05T02:35:31.611924Z",{"nct_id":241,"title":242,"phases":243,"status":12,"updated_at":96,"content_modified":244},"NCT07281716","Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC",[120],"2026-04-29T02:57:57.081395Z",{"nct_id":246,"title":247,"phases":248,"status":12,"updated_at":249,"content_modified":250},"NCT04165772","Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors",[19],"2026-08-26T02:19:11.399072Z","2026-07-05T05:32:16.775552Z",{"nct_id":252,"title":253,"phases":254,"status":12,"updated_at":255,"content_modified":256},"NCT07419841","A Phase 1 Study of the Safety and Tolerability of CTX-10726",[65],"2026-08-26T02:18:55.570428Z","2026-07-05T05:32:16.684256Z",{"nct_id":258,"title":259,"phases":260,"status":12,"updated_at":261,"content_modified":262},"NCT05784688","Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors",[120],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.298307Z",{"nct_id":264,"title":265,"phases":266,"status":12,"updated_at":267,"content_modified":268},"NCT06974110","Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors",[65],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:28.849469Z",{"nct_id":270,"title":271,"phases":272,"status":12,"updated_at":273,"content_modified":274},"NCT07094204","A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",[65],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.482220Z",{"nct_id":276,"title":277,"phases":278,"status":12,"updated_at":279,"content_modified":280},"NCT07001748","Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity",[52],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:27.952061Z",{"nct_id":282,"title":283,"phases":284,"status":12,"updated_at":285,"content_modified":286},"NCT07213609","A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors",[120],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:27.666743Z",{"nct_id":288,"title":289,"phases":290,"status":12,"updated_at":291,"content_modified":292},"NCT06795009","Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer",[65],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.984599Z",{"nct_id":294,"title":295,"phases":296,"status":12,"updated_at":297,"content_modified":298},"NCT06824363","ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w\u002FARID1a Mu",[38],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:26.849550Z",{"nct_id":300,"title":301,"phases":302,"status":12,"updated_at":303,"content_modified":304},"NCT03539822","Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies",[120],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:26.745155Z",{"nct_id":306,"title":307,"phases":308,"status":12,"updated_at":309,"content_modified":310},"NCT06562192","Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",[65],"2026-08-26T02:19:03.581490Z","2026-07-30T01:46:14.467786Z"]